This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
GSK forms collaboration with Angiochem around lysosomal storage disorders
05 Mar 2012
Angiochem Inc. (drug candidates capable of crossing the blood-brain barrier) has agreed to generate and develop for GlaxoSmithKline PLC an enzyme replacement therapy for an unspecified lysosomal storage disorder (LSD). GSK may expand the agreement to other LSDs, a group of rare inherited metabolic diseases caused by enzyme deficiencies that lead to build-up of toxic materials in the cells.
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?